Doug Treco

Douglas Treco, Ph.D., currently serves as CEO and has served as the chairman of our board of directors since May 2020. Dr. Treco was the Co-Founder, President, and Chief Executive Officer of Ra Pharmaceuticals, Inc., a biotechnology company focused on peptide and small molecule inhibitors of the complement pathway. The company was acquired in April 2020 by UCB S.A. for $2.5 billion. Its lead program, zilucoplan for the treatment of myasthenia gravis is currently under review for marketing approval in the United States and European Union.